Abiopharma

BioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte Quartal 2025 und informiert über operativen Fortschritt

MLTX INVESTOR NOTICE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

DocGo to Announce Third Quarter 2025 Results on Monday, November 10, 2025

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohns disease at two years

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)